Modality
Degrader
MOA
BCL-2i
Target
PD-L1
Pathway
Neuroinflam
RA
Development Pipeline
Preclinical
~Apr 2013
→ ~Jul 2014
Phase 1
~Oct 2014
→ ~Jan 2016
Phase 2
~Apr 2016
→ ~Jul 2017
Phase 3
~Oct 2017
→ ~Jan 2019
NDA/BLA
~Apr 2019
→ ~Jul 2020
Approved
Oct 2020
→ Apr 2028
ApprovedCurrent
NCT07030166
881 pts·RA
2021-11→TBD·Terminated
NCT08124484
263 pts·RA
2020-10→2026-12·Not yet recruiting
NCT06298776
1,683 pts·RA
2022-02→2028-04·Not yet recruiting
+1 more trial
3,344 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2025-07-198mo agoPh3 Readout· RA
2026-12-169mo awayPh3 Readout· RA
2028-04-282.1y awayPh3 Readout· RA
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Approved
Not yet…
Approved
Not yet…
Approved
Termina…
Approved
Not yet…
Catalysts
Ph3 Readout
2025-07-19 · 8mo ago
RA
Ph3 Readout
2026-12-16 · 9mo away
RA
Ph3 Readout
2028-04-28 · 2.1y away
RA
TerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07030166 | Approved | RA | Terminated | 881 | FEV1 |
| NCT08124484 | Approved | RA | Not yet recr... | 263 | BodyWt |
| NCT06298776 | Approved | RA | Not yet recr... | 1683 | PANSS |
| NCT06156472 | Approved | RA | Not yet recr... | 517 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D |